White Paper

The Impact of COVID-19 Comorbidities on Return to Work

ODG by MCG explores comorbidities identified (thus far) for increased risk in COVID-19 cases, impacts on return-to-work for post-COVID-19 infection, and current prognostic/mortality risk tools.

White Paper Summary

In 2020, the coronavirus disease 2019 (COVID-19) pandemic had a widespread impact and presented unprecedented challenges to many sectors of business, including the healthcare system. One facet of the pandemic where evidence is still being developed and analyzed is the impact of comorbidities on the disease course and potential return to work (RTW) considerations. Inadequate comorbidity management can lead to longer duration of acute illness, higher total healthcare costs, more temporary disability days, and higher litigation rates.


To learn more about ODG by MCG, please visit their website.

ODG, an MCG Health company, provides unbiased, evidence-based guidelines that unite payers, providers, and employers in the effort to confidently and effectively return employees to health.

More from Risk & Insurance

More from Risk & Insurance